Recent developments highlight Medicus Pharma's progress in clinical trial designs, regulatory compliance, leadership appointments, and Nasdaq listing status.

• Medicus Pharma regained Nasdaq compliance after meeting the minimum share price requirement following a 1-for-50 reverse stock split in October 2026 [N1].
• The company is advancing a multi-asset growth strategy after three years of expansion, focusing on clinical-stage assets despite recent stock price declines [N2].
• Medicus' CEO has actively sought lawmaker support for SkinJect in Gorlin Syndrome to aid development and awareness [N3].
• D. Boral Capital has maintained a buy recommendation on Medicus Pharma across multiple reports in late 2025 [N4][N6][N7][N8].
• Carolyn Bonner was appointed President and CFO in December 2025, strengthening executive leadership [N5].

Medicus Pharma's advancement of clinical programs such as Teverelix into streamlined Phase 2b/3 trials and positive regulatory feedback could enhance its development efficiency. The company's focus on rare diseases with unmet medical needs may provide opportunities for orphan drug designations and market exclusivity. Recent Nasdaq compliance restoration supports continued access to capital markets. Experienced leadership and board members with pharmaceutical and healthcare expertise may facilitate strategic execution.

Medicus Pharma faces significant financial challenges including a net loss of $15.2 million in Q3 2026 and a current ratio below 1, indicating liquidity constraints. The company is at risk of Nasdaq delisting due to market capitalization and shareholders' equity deficits, which could impair liquidity and capital raising. Clinical development risks remain high given the early-stage pipeline and regulatory uncertainties. Failure to maintain Nasdaq listing or raise sufficient capital could materially impact operations and continuation as a going concern.

Medicus Pharma's moat is primarily based on its clinical-stage pharmaceutical pipeline targeting rare diseases with limited existing treatment options. Its focus on orphan and underserved indications such as Gorlin Syndrome and basal cell carcinoma provides potential differentiation. The company has established regulatory interactions and clinical trial designs that may streamline development. However, as a clinical-stage company without commercial products, its competitive advantage depends on successful clinical development and regulatory approvals, which remain uncertain.

• Nasdaq Listing Compliance Risk: The company faces risk of delisting if it does not maintain minimum market capitalization, shareholders' equity, and share price requirements by November 16, 2026. Delisting could reduce liquidity, market visibility, and access to capital.
• Financial Condition and Liquidity Risk: Medicus Pharma reported a net loss of $15.2 million for Q3 2026 and had a current ratio of 0.65 as of September 30, 2026, indicating potential liquidity constraints that may affect its ability to fund operations and clinical development.
• Clinical Development Risk: The company's pipeline is in clinical stages with inherent risks including trial design, regulatory approvals, and successful commercialization. Failure in clinical trials or regulatory setbacks could adversely affect business prospects.
• Capital Raising and Debt Risk: The company may face challenges raising capital on acceptable terms. Secured promissory notes contain trigger events related to Nasdaq listing status that could increase debt obligations and default risk.